Combination therapy for treating advanced drug-resistant acute lymphoblastic leukemia

Drug-resistant acute lymphoblastic leukemia (ALL) patients do not respond to standard chemotherapy, and an urgent need exists to develop new treatment strategies. Our study exploited the presence of B-cell activating factor receptor (BAFF-R) on the surface of drug-resistant B-ALL cells as a therapeu...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Immunol Res
Prif Awduron: Vicioso, Yorleny, Gram, Hermann, Beck, Rose, Asthana, Abhishek, Zhang, Keman, Wong, Derek P., Letterio, John, Parameswaran, Reshmi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606383/
https://ncbi.nlm.nih.gov/pubmed/31138521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-19-0058
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg